Skip to main content

Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population

  • Feng Zang (a1), Ming Yue (a2), Yinan Yao (a1), Mei Liu (a1), Haozhi Fan (a1), Yue Feng (a3), Xueshan Xia (a3), Peng Huang (a1) and Rongbin Yu (a1)...

The high rate of chronic hepatitis C (CHC) was one of the key issues of global public health concern. Interferon (IFN) relevant genes were in the antiviral treatment pathway, not only influenced hepatitis C virus (HCV) spontaneous clearance, but also affected the IFN-mediated viral clearance. The aim of this study was to identify the association of interleukin 28B (IL28B), myxovirus resistance A (MxA) gene polymorphisms with HCV spontaneous clearance and therapeutic response in Chinese CHC patients. IL28B and MxA gene genotypes were detected among 231 CHC carriers, 428 subjects with HCV spontaneous clearance and 662 CHC patients with pegylated IFN-α and ribavirin (pegIFN-α/RBV) treatment. Patients with MxA rs2071430 TT genotype were more likely to develop HCV infection chronicity (additive model: odds ratio (OR) 1.22, 95% confidence interval (CI) 1.01–1.48, P = 0.042). IL28B rs1298075 variant genotypes (additive model: OR 0.58, 95% CI 0.34–0.98, P = 0.040) and MxA rs17000900 variant genotypes (additive model: OR 0.54, 95% CI 0.30–0.99, P = 0.048) were less likely to achieve a sustained virological response. The life table indicated that patients with IL28B rs1298075 AG genotype were slower to achieve a viral load <500 copies/ml (P = 0.018). During the treatment, the downward trend in viral load was different among each IL28B rs1298075 genotype, especially in subgroup with a baseline HCV-RNA >106 copies/ml (all P < 0.05). This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-α/RBV among Chinese CHC patients.

Corresponding author
Author for correspondence: Rongbin Yu, Peng Huang, E-mail:,
Hide All

These authors contributed equally to this work.

Hide All
1. Matsuura, K, et al. (2015) Natural history of hepatitis C virus infection. Nihon Rinsho 73(2): 195200.
2. Welzel, T, et al. (2017) Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. Journal of Hepatology 67(2): 224236.
3. Kuiken, C, et al. (2009) Nomenclature and numbering of the hepatitis C virus. Methods in Molecular Biology 510: 3353.
4. Hijikata, M, et al. (2000) Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt-88) correlated with the response of hepatitis C patients to interferon. Intervirology 43(2): 124127.
5. Tanaka, Y, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature Genetics 41(10): 11051109.
6. Suppiah, V, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics 41(10): 11001104.
7. Ge, D, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262): 399401.
8. Zheng, H, et al. (2015) IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: a systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 39(5): 576583.
9. Kalantari, H, et al. (2014) Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus. Journal of Research in Medical Sciences 19(11): 10621067.
10. Par, A, et al. (2013) IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection. Orvosi Hetilap 154(32): 12611268.
11. Cui, Q, et al. (2011) Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infection, Genetics and Evolution 11(7): 16821689.
12. Omata, M, et al. (2016) APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatology International 10(5): 681701.
13. Xu, Y, et al. (2016) A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. Journal of Human Genetics 61(4): 301305.
14. Domagalski, K, et al. (2016) Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. World Journal of Gastroenterology 22(41): 91869195.
15. Polo, ML, et al. (2017) Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Review of Anti-infective Therapy 15(8): 737746.
16. Welzel, TM, et al. (2016) Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 65(11): 18611870.
17. Hlaing, N, et al. (2017) Safety and efficacy of sofosbuvir-based DAA regimens for hepatitis C virus genotypes 1–4 and 6 in Myanmar: real-world experience. Journal of Viral Hepatitis 24(11): 927935.
18. Bersoff-Matcha, SJ, et al. (2017) Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system. Annals of Internal Medicine 166(11): 792798.
19. Laboratory Centre for Disease Control (1995) Guidelines and recommendations on the prevention and control of hepatitis C. Canada Communicable Disease Report 21(Suppl. 2): 118, 1–21.
20. Michelin, A, et al. (2010) Infection control guidelines for prevention of health care-associated transmission of hepatitis B and C viruses. Clinics in Liver Disease 14(1): 119136.
21. Wu, M, et al. (2016) Vitamin D level and vitamin D receptor genetic variations contribute to HCV infection susceptibility and chronicity in a Chinese population. Infection, Genetics and Evolution 41: 146152.
22. Urban, TJ, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52(6): 18881896.
23. O'Connor, KS, et al. (2016) IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes and Immunity 17(6): 328334.
24. Chen, H, et al. (2014) Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. Journal of Biomedical Research 28(6): 476483.
25. Shaker, OG, et al. (2015) Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4. Cell Biochemistry and Biophysics 71(2): 617625.
26. Hu, CH, et al. (2012) Association between single nucleotide polymorphisms in −88 and −123 loci of MxA gene promoter region and HCV susceptibility and IFN-alpha efficacy. Chinese Journal of Cellular and Molecular 28(12): 13071310.
27. Liu, T, et al. (2014) IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS ONE 9(3): e91316.
28. Li, W, et al. (2011) Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver International 31(8): 11181126.
29. Lunge, VR, et al. (2012) IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a southern Brazilian HIV type 1 population. AIDS Research and Human Retroviruses 28(2): 215219.
30. Boglione, L, et al. (2017) Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. Infection Genetics and Evolution 53: 195198.
31. Thomas, DL, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265): 798801.
32. Prokunina-Olsson, L, et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature Genetics 45(2): 164171.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary materials

Zang et al supplementary material
Tables S1-S2

 Word (50 KB)
50 KB


Full text views

Total number of HTML views: 5
Total number of PDF views: 51 *
Loading metrics...

Abstract views

Total abstract views: 593 *
Loading metrics...

* Views captured on Cambridge Core between 22nd December 2017 - 22nd June 2018. This data will be updated every 24 hours.